Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05465785
Other study ID # JSVCT141
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 20, 2022
Est. completion date December 30, 2023

Study information

Verified date March 2024
Source WestVac Biopharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with immunization procedures 0, 21, 42 days .


Description:

This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with vaccination course 0, 21, 42 days. 892 subjects aged 18-59 years are recruited and randomly inoculated in a 1:1 ratio from a pilot or commercial batch of Recombinant COVID-19 Vaccine (Sf9 Cell).


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date December 30, 2023
Est. primary completion date March 11, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 59 Years
Eligibility Inclusion Criteria: - Subjects aged from 18-59 years. - Signed informed consent forms of the subjects have been obtained. - Able and willing to comply with the requirements of the clinical trial protocol and able to complete approximately 8 months of study follow-up. - Axillary temperature < 37.3?. Subjects who fulfill all the required conditions for receiving the candidate vaccine as established by medical history and physical examination and determined by investigators. Exclusion Criteria: - Positive SARS-CoV-2 antibodies (IgG or IgM) screening results. - Positive SARS-CoV-2 Antigen screening results. - History of COVID-19 vaccination. - Previously diagnosed with COVID-19 infection. - History of HIV infection. - History or family history of convulsion, epilepsy, encephalopathy and psychosis. - Allergy to any component of the candidate vaccine, severe allergy to vaccine in the past, and history of allergy. - Women with positive urine pregnancy test results, pregnant, lactating women, or women who have a pregnancy plan during the study. - Patients with acute febrile diseases and infectious diseases. - Patients with a history of SARS. - Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by drugs, etc. - Serious chronic diseases or progressive stage of a disease that cannot be steadily controlled, such as asthma, diabetes mellitus, thyroid disease, etc. - Congenital or acquired angioedema/angioneurotic edema. - Urticaria 1 year before receiving the candidate vaccine. - Asplenia or functional asplenia. - Thrombocytopenia or other coagulation disorders (which may contraindicate intramuscular injection). - Fear of needles. - Any immunosuppressant, antiallergic therapy, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months. - Blood products within 4 months prior to receiving the candidate vaccine. - Any other investigational medicine(s) within 1 month prior to the candidate vaccine. - Any live attenuated vaccine within 1 month prior to the candidate vaccine. - Any subunit vaccine or inactivated vaccine within 14 days prior to the candidate vaccine. - Receiving antituberculosis treatment. - Medical, psychological, social or other factors, which in the discretion of the investigators fail to meet the requirements in the trial protocol or affect the subjects to sign the ICFs. Exclusion criteria for the second/third dose: In this trial, the second/third vaccination may be stopped in some cases. They include systemic allergic reaction, severe hypersensitivity, or intolerable Grade 3 or above ARs after the previous dose of vaccine. If these reactions occur, the subjects should not continue to receive the second/third vaccination.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant COVID-19 vaccine (Sf9 cell)
This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Locations

Country Name City State
China Jiangsu Provincial Center for Disease Control and Prevention Huai'an Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
WestVac Biopharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of adverse reactions(ARs). The incidence of ARs within 7 days after each vaccination. Day 0 to day 7
Primary Anti-SARS-CoV-2 specific neutralizing antibodies expressed as geometric mean titer (GMT)and seroconversion rate (SCR). The GMT and SCR of anti-SARS-CoV-2 specific neutralizing antibodies (euvirus) of the subjects on day 30 after the third vaccination. Day 72
Secondary The incidence of ARs. The incidence of ARs from Day 0 to Day 72. Day 0 to Day 72
Secondary The incidence of adverse events (AEs). The incidence of adverse events (AEs) from Day 0 to Day 72. Day 0 to Day 72
Secondary The incidence of serious adverse events (SAEs). The incidence of SAEs from day 0 through 6 months after the third vaccination. Day 0 to 6 months after the third vaccination.
Secondary The Geometric Mean Fold Increase (GMI) of the anti-SARS-COV-2 specific neutralizing antibody. The GMI of the anti-SARS-COV-2 specific neutralizing antibody of the subjects on day 30 after the third vaccination. Day 72
Secondary The Geometric Mean Titre (GMT), Seroconversion Rate (SCR) and GMI of anti-SARS-COV-2 S-RBD Immunoglobulin (IgG) antibody The GMT, SCR and GMI of anti-SARS-COV-2 S-RBD IgG antibody of the subjects on day 30 after the third vaccination Day 72
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure